PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)

• Amer M. Zeidan,
• Karen Mosher,
• Sonia Souza,
• Beloo Mirakhur,
• Harold Keer,
• Jason Taylor

Affiliations

Amer M. Zeidan

1 Yale University and Yale Cancer Center, New Haven, United States

Karen Mosher

2 Astex Pharmaceuticals, Inc., Pleasanton, United States

Sonia Souza

2 Astex Pharmaceuticals, Inc., Pleasanton, United States

Beloo Mirakhur

2 Astex Pharmaceuticals, Inc., Pleasanton, United States

Harold Keer

2 Astex Pharmaceuticals, Inc., Pleasanton, United States

Jason Taylor

2 Astex Pharmaceuticals, Inc., Pleasanton, United States